Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia

Appraisal committee members

The appraisal committees are standing advisory committees of NICE. Members are appointed for a 3‑year term. A list of the committee members who took part in the discussions for this appraisal appears below. There are 4 appraisal committees, each with a chair and vice chair. Each appraisal committee meets once a month, except in December when there are no meetings. Each committee considers its own list of technologies, and ongoing topics are not moved between committees.

Committee members are asked to declare any interests in the technology to be appraised. If it is considered there is a conflict of interest, the member is excluded from participating further in that appraisal.

The minutes of each appraisal committee meeting, which include the names of the members who attended and their declarations of interests, are posted on the NICE website.

Professor Andrew Stevens
Chair of Appraisal Committee C, Professor of Public Health, University of Birmingham

Professor Eugene Milne
Vice Chair of Appraisal Committee C, Director of Public Health, City of Newcastle upon Tyne

Professor Kathryn Abel
Institute of Brain and Behaviour Mental Health, University of Manchester

Mr David Chandler
Lay Member

Mrs Gail Coster
Advanced Practice Sonographer, Mid Yorkshire Hospitals NHS Trust

Professor Peter Crome
Honorary Professor, Department of Primary Care and Population Health, University College London

Professor Rachel A Elliott
Lord Trent Professor of Medicines and Health, University of Nottingham

Dr Nigel Langford
Consultant in Clinical Pharmacology and Therapeutics and Acute Physician, Leicester Royal Infirmary

Dr Andrea Manca
Health Economist and Senior Research Fellow, University of York

Dr Patrick McKiernan
Consultant Pediatrician, Birmingham Children's Hospital

Dr Iain Miller
Founder and Chief Executive Officer, Health Strategies Group

Professor Stephen O'Brien
Professor of Haematology, Newcastle University

Dr Anna O'Neill
Deputy Head of Nursing and Health Care School, Senior Clinical University Teacher, University of Glasgow

Professor Peter Selby
Consultant Physician, Central Manchester University Hospitals NHS Foundation Trust

Professor Matt Stevenson
Technical Director, School of Health and Related Research, University of Sheffield

Dr Paul Tappenden
Reader in Health Economic Modelling, School of Health and Related Research, University of Sheffield

Professor Robert Walton
Clinical Professor of Primary Medical Care, Barts and The London School of Medicine and Dentistry

Dr Judith Wardle
Lay Member

NICE project team

Each technology appraisal is assigned to a team consisting of 1 or more health technology analysts (who act as technical leads for the appraisal), a technical adviser and a project manager.

Jasdeep Hayre
Technical Lead

Linda Landells
Technical Adviser

Lori Farrar
Project Manager

Sources of evidence considered by the committee

The evidence review group (ERG) report for this appraisal was prepared by Aberdeen Health Technology Assessment (HTA) Group:

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Companies or sponsors were also invited to make written submissions. Professional or expert, patient or carer groups, and other consultees had the opportunity to make written submissions. Companies or sponsors, professional or expert, patient or carer groups, and other consultees also have the opportunity to appeal against the final appraisal determination.

Company or sponsor:

Professional or expert, and patient or carer groups:

Other consultees:

Commentator organisations (did not provide written evidence and without the right of appeal):

The following individuals were selected from clinical expert and patient expert nominations from the consultees and commentators. They gave their expert personal view on ezetimibe for treating primary heterozygous‑familial and non‑familial hypercholesterolaemia by attending the initial committee discussion and providing a written statement to the committee. They were also invited to comment on the ACD.

Representatives from the following company attended committee meetings. They contributed only when asked by the committee chair to clarify specific issues and comment on factual accuracy.

ISBN: 978-1-4731-1706-8